Maxime Verhoeven

35 Systematic review of remission-induction strategies in early RA 31. ter Wee, M. M. et al. Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial. Ann. Rheum. Dis. 74 , 1233–1240 (2015). 32. Verschueren, P. et al. Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial. Ann. Rheum. Dis. 76 , 511–520 (2017). 33. Bergstra, A. S., Landewé, R. B., Huizinga, T. W. & Allaart, C. F. Rheumatoid arthritis patients with continued low disease activity have similar outcomes over 10 years, regardless of initial therapy. Ann. Rheum. Dis. 56 , 1721-1728 (2017). 34. Emery, P. et al. Efficacy and safety of subcutaneous golimumab in methotrexate-naive patients with rheumatoid arthritis: five-year results of a randomized clinical trial. Arthritis Care Res. 68 , 744–752 (2016). 35. Keystone, E. C. et al. Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension. J. Rheumatol. 41 , 5–14 (2014). 36. Konijn, N. P. C. et al. Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial. Rheumatol. 56 , 1586–1596 (2017). 37. Markusse, I. M. et al. Long-term outcomes of patients with recent-onset rheumatoid arthritis after 10 years of tight controlled treatment: a randomized trial. Ann. Intern. Med. 164 , 523–531 (2016). 38. Verhoeven, M. et al. U-act-early trial 3 years follow-up. The longer effectiveness of treat-to-target strategies in early RA with tocilizumab, methotrexate, or their combination. Ann. Rheum. Dis. 77 , 560 (2018). 39. van Nies, J. A. B. et al. Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts. Ann. Rheum. Dis. 74 , 806–812 (2015). 40. Singh, J. A. et al. Biologics or tofacitinib for people with rheumatoid arthritis naive tomethotrexate: a systematic review and network meta-analysis. Cochrane Database Syst. Rev. 2017 , CD012657 (2017). 41. Teitsma, X. M. et al. Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies. Rheumatol. 57 , 309–317 (2018). 42. Steunebrink, L. M. M. et al. Radiographic progression in early rheumatoid arthritis patients following initial combination versus step-up treat-to-target therapy in daily clinical practice: results from the DREAM registry. BMC Rheumatol. 2 , 1–10 (2018). 2